Safiglipron
Sources
registry, as of 2026-09-24Stale
https://clinicaltrials.gov/study/NCT07528027
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 648. Conditions Hypertension With Overweight or Obesity. The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
ClinicalTrials.gov NCT07528027 protocol and results modules
registry, as of 2026-07-27Stale
https://clinicaltrials.gov/study/NCT06904105
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 556. Conditions Overweight; Obesity. The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
ClinicalTrials.gov NCT06904105 protocol and results modules
registry, as of 2025-04-13Stale
https://clinicaltrials.gov/study/NCT06250946
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 235. Conditions Overweight and Obesity. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in Chinese Obese Subjects.
ClinicalTrials.gov NCT06250946 protocol and results modules
registry, as of 2025-12-29Stale
https://clinicaltrials.gov/study/NCT06820099
Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 225. Conditions Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity. This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.
ClinicalTrials.gov NCT06820099 protocol and results modules
registry, as of 2025-11-17Stale
https://clinicaltrials.gov/study/NCT06671821
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 81. Conditions Chronic Weight Management. The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.
ClinicalTrials.gov NCT06671821 protocol and results modules
registry, as of 2026-08-24Stale
https://clinicaltrials.gov/study/NCT06621316
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 74. Conditions Overweight or Obesity. The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.
ClinicalTrials.gov NCT06621316 protocol and results modules
registry, as of 2026-06-29Stale
https://clinicaltrials.gov/study/NCT07269756
A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Shandong Suncadia Medicine Co., Ltd.. Enrollment 40. Conditions Obesity; Overweight. This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.
ClinicalTrials.gov NCT07269756 protocol and results modules
publication, as of 2026-08-05Stale
https://pubmed.ncbi.nlm.nih.gov/42331800/
without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. HRS-7535 is an orally active small-molecule glucagon-like peptide-1 receptor agonist that showed weight-loss potential in a phase 1 study. In this completed multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 29 centers in China, w
PMID 42331800